Meanwhile, a post-hoc analysis of the STEP 1 and STEP 4 trials showed that semaglutide 2.4 mg was associated with an approximately 60% reduction of the 10-years risk of T2D according to the Cardiometabolic Disease Staging (CMDS) calculator, regardless of patients baseline glycemic status 74
GLP-1s are in part "anti-desire" drugs and I'm curious what a society without embodied desire looks like
Although we strive to strictly provide accurate and up to date general information, content available on this site is not a substitute for professional medical advice, and you should not rely solely on the information provided here
In the present study, we used only male mice to minimize variability introduced by the estrous cycle in females, which is known to influence toxicity, body weight, food intake, and metabolic parameters [31,32,33,34,35,36]